International Collaborative Ovarian Neoplasm studies (2): a trial of CAP versus carboplatin in advanced ovarian cancer
| ISRCTN | ISRCTN48215558 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN48215558 |
| Secondary identifying numbers | ICON2 |
- Submission date
- 28/02/2001
- Registration date
- 28/02/2001
- Last edited
- 09/07/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Ms Claire Amos
Scientific
Scientific
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | |
| Study objectives | To compare cyclophosphamide, doxorubicin and cisplatin (CAP) with single-agent carboplatin in patients with advanced ovarian cancer. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Ovarian cancer |
| Intervention | 1. Cyclophosphamide, doxorubicin and cisplatin (CAP) 2. Single-agent carboplatin |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Cyclophosphamide, doxorubicin, cisplatin, carboplatin |
| Primary outcome measure | 1. Survival time 2. Progression-free survival |
| Secondary outcome measures | Not provided at time of registration |
| Overall study start date | 01/01/1991 |
| Completion date | 31/12/1996 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Female |
| Target number of participants | 2000 in 9 countries |
| Key inclusion criteria | 1. Chemotherapy indicated 2. No previous malignancy 3. No prior radiotherapy or chemotherapy 4. No contraindication to chemotherapy |
| Key exclusion criteria | Does not meet inclusion criteria |
| Date of first enrolment | 01/01/1991 |
| Date of final enrolment | 31/12/1996 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
MRC Clinical Trials Unit
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Sponsor information
Medical Research Council (MRC) (UK)
Research council
Research council
20 Park Crescent
London
W1B 1AL
United Kingdom
| Phone | +44 (0)20 7636 5422 |
|---|---|
| clinical.trial@headoffice.mrc.ac.uk | |
| Website | http://www.mrc.ac.uk |
Funders
Funder type
Research council
Medical Research Council (MRC) (UK)
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- Medical Research Council (United Kingdom), UK Medical Research Council, MRC
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 14/11/1998 | Yes | No |
